Clinical trials of CAR-T cells in China

Novel immunotherapeutic agents targeting tumor-site microenvironment are revolutionizing cancer therapy. Chimeric antigen receptor (CAR)-engineered T cells are widely studied for cancer immunotherapy. CD19-specific CAR-T cells, tisagenlecleucel, have been recently approved for clinical application....

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Bingshan, Song, Yongping, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651613/
https://www.ncbi.nlm.nih.gov/pubmed/29058636
http://dx.doi.org/10.1186/s13045-017-0535-7
_version_ 1783272928479019008
author Liu, Bingshan
Song, Yongping
Liu, Delong
author_facet Liu, Bingshan
Song, Yongping
Liu, Delong
author_sort Liu, Bingshan
collection PubMed
description Novel immunotherapeutic agents targeting tumor-site microenvironment are revolutionizing cancer therapy. Chimeric antigen receptor (CAR)-engineered T cells are widely studied for cancer immunotherapy. CD19-specific CAR-T cells, tisagenlecleucel, have been recently approved for clinical application. Ongoing clinical trials are testing CAR designs directed at novel targets involved in hematological and solid malignancies. In addition to trials of single-target CAR-T cells, simultaneous and sequential CAR-T cells are being studied for clinical applications. Multi-target CAR-engineered T cells are also entering clinical trials. T cell receptor-engineered CAR-T and universal CAR-T cells represent new frontiers in CAR-T cell development. In this study, we analyzed the characteristics of CAR constructs and registered clinical trials of CAR-T cells in China and provided a quick glimpse of the landscape of CAR-T studies in China.
format Online
Article
Text
id pubmed-5651613
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-56516132017-10-26 Clinical trials of CAR-T cells in China Liu, Bingshan Song, Yongping Liu, Delong J Hematol Oncol Rapid Communication Novel immunotherapeutic agents targeting tumor-site microenvironment are revolutionizing cancer therapy. Chimeric antigen receptor (CAR)-engineered T cells are widely studied for cancer immunotherapy. CD19-specific CAR-T cells, tisagenlecleucel, have been recently approved for clinical application. Ongoing clinical trials are testing CAR designs directed at novel targets involved in hematological and solid malignancies. In addition to trials of single-target CAR-T cells, simultaneous and sequential CAR-T cells are being studied for clinical applications. Multi-target CAR-engineered T cells are also entering clinical trials. T cell receptor-engineered CAR-T and universal CAR-T cells represent new frontiers in CAR-T cell development. In this study, we analyzed the characteristics of CAR constructs and registered clinical trials of CAR-T cells in China and provided a quick glimpse of the landscape of CAR-T studies in China. BioMed Central 2017-10-23 /pmc/articles/PMC5651613/ /pubmed/29058636 http://dx.doi.org/10.1186/s13045-017-0535-7 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Rapid Communication
Liu, Bingshan
Song, Yongping
Liu, Delong
Clinical trials of CAR-T cells in China
title Clinical trials of CAR-T cells in China
title_full Clinical trials of CAR-T cells in China
title_fullStr Clinical trials of CAR-T cells in China
title_full_unstemmed Clinical trials of CAR-T cells in China
title_short Clinical trials of CAR-T cells in China
title_sort clinical trials of car-t cells in china
topic Rapid Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651613/
https://www.ncbi.nlm.nih.gov/pubmed/29058636
http://dx.doi.org/10.1186/s13045-017-0535-7
work_keys_str_mv AT liubingshan clinicaltrialsofcartcellsinchina
AT songyongping clinicaltrialsofcartcellsinchina
AT liudelong clinicaltrialsofcartcellsinchina

Ejemplares similares